Are We Overusing Coagulation Studies in the Emergency Department?

Table 1

Clinical and demographic profile of 1,754 patients who were ordered coagulation profile testing.

Characteristics	N = 1,754
Age in years, mean ± SD	42.1 ± 18.5
Gender, n (%)
Male	811 (46.2%)
Female	943 (53.8%)
Chief complaints
GI related complaints	392 (22.3%)
CNS related/stroke	169 (9.6%)
Trauma	121 (6.9%)
Bleeding and bruising	117 (6.7%)
Dyspnea	96 (5.5%)
Palpitation	58 (3.3%)
Urinary symptoms	57 (3.2%)
Leg pain and swelling	54 (3.1%)
Fever	38 (2.2%)
Back pain	31 (1.8%)
Others
Toxic ingestion	13 (0.7%)
Psychiatric symptoms	5 (0.3%)
None (sent to do coagulation profile)	9 (0.5%)
Comorbidities, n (%)
None	696 (39.7%)
Diabetes mellitus	417 (23.8%)
Hypertension	386 (22.0%)
Dyslipidemia	167 (9.5%)
Coronary artery disease	96 (5.5%)
Malignancy	56 (3.2%)
End-stage renal disease	38 (2.2%)
Atrial fibrillation	29 (1.7%)
Liver disease	29 (1.7%)
Thromboembolic disease	21 (1.2%)
Ischemic stroke	20 (1.1%)
Hypothyroidism	76 (4.3%)
Others
Systemic lupus erythematosus	8 (0.5%)
Cardiomyopathy	7 (0.4%)
Hemophilia A	3 (0.2%)
Antiphospholipid syndrome	3 (0.2%)
Carotid stenosis	1 (0.1%)
Medications used
Aspirin	173 (9.8%)
Enoxaparin	37 (2.1%)
Rivaroxaban	29 (1.7%)
Warfarin	18 (1.0%)
Aspirin and clopidogrel	13 (0.7%)
Apixaban	10 (0.6%)
Others
Heparin and warfarin	1 (0.06%)
Dabigatran	1 (0.06%)